Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (Nasdaq: KURA) is a biopharmaceutical company focused on precision medicines for cancer, and its news flow reflects the evolution of this strategy. Company announcements highlight progress with KOMZIFTI (ziftomenib), an oral menin inhibitor approved in the United States for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.
News items for KURA commonly cover regulatory milestones, clinical data and commercial updates. Recent releases describe full FDA approval of KOMZIFTI, its addition to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as a Category 2A recommended option for relapsed or refractory NPM1-mutated AML, and the start of U.S. commercial sales. Kura also reports on its collaboration with Kyowa Kirin, including milestone payments tied to clinical and commercial events.
Investors following KURA news can expect detailed coverage of clinical trial readouts from programs such as KOMET-001, KOMET-007 and KOMET-017, which evaluate ziftomenib across newly diagnosed and relapsed or refractory AML, often in combination with regimens like cytarabine/daunorubicin and venetoclax/azacitidine. Additional news addresses the company’s farnesyl transferase inhibitor programs, darlifarnib and tipifarnib, and their activity in solid tumors.
Kura’s press releases also include corporate updates such as financial results, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in scientific and investor conferences. For readers tracking KURA, this news page offers a centralized view of key developments in its precision oncology pipeline, regulatory interactions, collaborations and commercialization activities.
Kura Oncology reported promising results from a Phase 2 study of tipifarnib, showing a 56% overall response rate and a median overall survival of 32.8 months in patients with advanced angioimmunoblastic T-cell lymphoma (AITL). Conducted on 65 patients, the study highlighted the effectiveness of farnesyl transferase inhibition in treating this aggressive cancer type. The response rate for AITL patients was notably high at 56%. Tipifarnib was well-tolerated, with common side effects being hematological and gastrointestinal. These findings underscore the potential of tipifarnib in cancer treatments.
Kura Oncology announced new preclinical findings for KO-539, a selective menin inhibitor, at the ASH Annual Meeting in Atlanta. These data demonstrate KO-539's ability to induce growth inhibition and differentiation in AML cells with KMT2A rearrangements or NPM1 mutations. The combination of KO-539 with the standard of care, venetoclax, shows synergistic effects, enhancing survival in aggressive AML models. KO-539 is currently in a Phase 1b clinical trial for relapsed/refractory AML, with an Orphan Drug Designation from the FDA.
Kura Oncology announced a partial clinical hold on its KOMET-001 Phase 1b study of KO-539 for relapsed or refractory acute myeloid leukemia (AML) due to a Grade 5 serious adverse event (a patient death) linked to differentiation syndrome. Current patients may continue treatment, but new enrollments are halted. Kura is collaborating with the FDA to lift the hold. As a result, the company has suspended guidance on enrollment completion and the recommended Phase 2 dose of KO-539 until clarity is achieved regarding the hold.
Kura Oncology announced that its CEO, Troy Wilson, will participate in two virtual investor conferences. The first is a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021, at 11:20 a.m. ET. The second is at the JMP Securities Hematology and Oncology Summit on December 7, 2021, at 2:20 p.m. ET. Audio webcasts of both events will be available on Kura's website, with archived replays accessible afterward. Kura is focused on developing precision medicines for cancer treatment, with ongoing trials for promising drug candidates.
Kura Oncology reported its Q3 2021 financial results with a net loss of $33.4 million, compared to $23.8 million in Q3 2020. The company continues to enroll patients in its Phase 1b study of KO-539 for AML, with plans for a comprehensive development strategy. Kura activated the first site for the Phase 1/2 trial of tipifarnib plus alpelisib in HNSCC. As of September 30, 2021, Kura holds $543.4 million in cash, providing a runway into 2024. The upcoming ASH presentation will discuss the potential of KO-539 in combination with venetoclax.
Kura Oncology, Inc. (Nasdaq: KURA) announced its participation in the Credit Suisse 30th Annual Healthcare Conference. The event features a virtual fireside chat with CEO Troy Wilson on November 9, 2021, at 3:30 p.m. ET. Investors can access a live audio webcast on Kura's website, with a replay available afterward. Kura specializes in precision medicines for cancer, focusing on small molecule drug candidates. Key programs include KO-539 for relapsed/refractory AML and Tipifarnib for HRAS mutant head and neck cancer, highlighting the company's innovative approach to oncology.
Kura Oncology, Inc. (Nasdaq: KURA) will release its third quarter 2021 financial results on November 4, 2021, after U.S. markets close. A webcast and conference call, scheduled for 4:30 p.m. ET / 1:30 p.m. PT, will provide financial insights and a corporate update. The call can be accessed by domestic and international callers with specific dial-in information. Kura focuses on innovative cancer treatments, including KO-539 for AML and Tipifarnib for HRAS mutant HNSCC, highlighting its commitment to precision medicine.
Kura Oncology (Nasdaq: KURA) has appointed Teresa Bair as Chief Legal Officer and Corporate Secretary. Bair brings over 25 years of legal experience, recently serving as General Counsel at Athenex, where she assisted in multiple NDA filings and an FDA approval. Kura's President, Troy Wilson, emphasized her expertise in drug development, crucial for advancing their oncology drug pipeline. Kura focuses on precision medicines for cancer, with pipeline candidates like KO-539 and tipifarnib, which has gained Breakthrough Therapy Designation.
Kura Oncology (Nasdaq: KURA) announced that Troy Wilson, Ph.D., J.D., CEO, will participate in two virtual investor conferences. He will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, with an on-demand recording available starting at 7:00 a.m. ET. Additionally, he will engage in a fireside chat at the Cantor Global Healthcare Conference on September 27, 2021, at 3:20 p.m. ET. Audio webcasts of both events will be accessible on Kura's website, with archived replays available after both events.
Kura Oncology reported its Q2 2021 results, highlighting key advancements in clinical trials and collaborations. The first patients have been dosed in the Phase 1b cohorts for KO-539, a menin inhibitor targeting relapsed/refractory AML. A collaboration with Novartis aims to assess tipifarnib with alpelisib in HNSCC. Kura has also nominated KO-2806 as its lead candidate in a new farnesyl transferase program. Financially, the company reported a net loss of $33.7 million with $567.5 million in cash reserves expected to sustain operations into 2024.